Platform to predict drug interactions in liver transplant patients
Development of a Pharmaco-proteomic Platform to Evaluate Potential Drug Interactions and Their Clinical Impact in Liver Transplant Patients Undergoing Multidrug Treatment
Pontificia Universidad Catolica de Chile · NCT06682325
This study is testing a new computer tool to help doctors predict kidney problems in liver transplant patients by looking at how different medications might interact with each other.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 48 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pontificia Universidad Catolica de Chile (other) |
| Locations | 3 sites (Santiago, Santiago Metropolitan and 2 other locations) |
| Trial ID | NCT06682325 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data to enhance the prediction of kidney failure in liver transplant patients in the ICU. By designing a multidrug web computing platform, the study will compile information on drug-drug interactions and integrate proteomic data from patients. The goal is to empower healthcare professionals with tools to predict clinical outcomes and devise personalized therapeutic interventions, ultimately improving patient care in liver transplantation.
Who should consider this trial
Good fit: Ideal candidates for this study are liver transplant patients undergoing surgery at UC Christus Hospital.
Not a fit: Patients on renal replacement therapy or those without available clinical or pharmacological registry will not benefit from this study.
Why it matters
Potential benefit: If successful, this platform could significantly improve the prediction and management of kidney failure in liver transplant patients, leading to better patient outcomes.
How similar studies have performed: While the integration of proteomics and drug interaction modeling is a novel approach, similar studies have shown promise in improving patient outcomes in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Liver transplant patients undergoing surgery at UC Christus Hospital Exclusion Criteria: * Patients on renal replacement therapy * Patients for whom no clinical or pharmacological registry is available
Where this trial is running
Santiago, Santiago Metropolitan and 2 other locations
- Hospital ClínicoUC-Christus — Santiago, Santiago Metropolitan, Chile (RECRUITING)
- Pontificia Universidad Católica de Chile — Santiago, Santiago Metropolitan, Chile (ACTIVE_NOT_RECRUITING)
- Universidad de Valparaíso — Valparaíso, Valparaiso, Chile (ACTIVE_NOT_RECRUITING)
Study contacts
- Principal investigator: Nelson Barrera, PhD — Pontificia Universidad Catolica de Chile
- Study coordinator: Nelson Barrera, PhD
- Email: nbarrerr@uc.cl
- Phone: 56987687058
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Drug-drug Interaction, Liver Transplantation